Heavy chain only antibodies to PDGF

Patent metadata

Field	Value
Publication number	US-11028163-B2
Application number	US-201916425140-A
Country	US
Kind code	B2
Filing date	May 29, 2019
Priority date	Aug 14, 2015
Publication date	Jun 8, 2021
Grant date	Jun 8, 2021

Abstract

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.

First claim

What is claimed is:

1. A method of treating an ophthalmologic disorder comprising administering to a subject in need thereof a heavy-chain only antibody (HCAb) comprising homodimeric variable heavy chain (VH) regions wherein each VH region comprises:
a CDR1 having the amino acid sequence of SEQ ID NO:23;
a CDR2 having the amino acid sequence of SEQ ID NO:24; and
a CDR3 having the amino acid sequence of SEQ ID NO:25;
wherein the HCAb retains its specificity for PDGF-BB; and
wherein the HCAB binds to PDGF-BB and treats the ophthalmologic disorder, and wherein the ophthalmologic disorder is selected from the group consisting of dry age-related macular degeneration, wet age-related macular degeneration, choroidal neovascularization (CNV), cystoid macula edema (CME), myopia-associated choroidal neovascularization, vascular streaks, diabetic macular edema (DME), macular edema, retinal vein occlusion, abnormal corneal angiogenesis, pterygium conjunctivae, subretinal edema, or intraretinal edema.

2. The method of claim 1 , wherein the VH region has at least 85% identity to SEQ ID NO:22.

3. The method of claim 2 , wherein the VH region has at least 90% identity to SEQ ID NO:22.

4. The method of claim 2 , wherein the VH region has at least 93% identity to SEQ ID NO:22.

5. The method of claim 2 , wherein the VH region has at least 96% identity to SEQ ID NO:22.

6. The method of claim 2 , wherein the VH region has at least 98% identity to SEQ ID NO:22.

7. The method of claim 1 , wherein the VH region comprises SEQ ID NO:22.

8. The method of claim 1 , wherein the abnormal corneal angiogenesis is as a result of keratitis, corneal transplantation, keroplasty or hypoxia.

Assignees

• Allergan Inc

Inventors

• Liang Yanbin
• Gil Daniel W

Classifications

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K2317/522

  CH1 domain · CPC title

• C07K2317/64

  comprising a combination of variable region and constant region components · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title